文献速递肝胆胰外科胃肠外科

APC与PIK3CA双突变预测结直肠癌肝转移患者病理缓解与生存

APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases.
PubMed 文献 · Ann Surg · 2020-01-01

该研究纳入396例接受术前化疗及肝切除的结直肠癌肝转移患者,分析APC与PIK3CA双突变与病理缓解及生存的关系。结果显示双突变患者无复发生存和总生存均更差,且双突变是病理缓解和总生存的独立预测因素;在157例仅接受化疗的独立队列中双突变同样与更差生存相关。

要点

  • APC与PIK3CA双突变患者肝切除后3年RFS仅3.1%,3年OS仅44%,均显著差于无双突变者。
  • 双突变是总生存的独立不良预测因素(HR 3.09,P<0.001),也是主要病理缓解的独立负向预测因素。
  • 贝伐珠单抗使用、肿瘤<3 cm、RAS野生型及无双突变是主要病理缓解的独立预测因素。

核心结论

  • APC与PIK3CA双突变预测结直肠癌肝转移患者对术前化疗反应差且生存不佳。

研究设计与样本

  • 回顾性分析396例原发结直肠癌且已知体细胞突变状态、接受肝切除的结直肠癌肝转移患者(2005-2015年),另用157例仅接受化疗的结直肠癌肝转移患者独立队列验证双突变的预后价值。

主要发现

  • 主要病理缓解的独立预测因素包括贝伐珠单抗使用(OR 2.22;P=0.001)、肿瘤<3 cm(OR 1.97;P=0.004)、RAS野生型(OR 2.00;P=0.003)及无双突变(OR 2.91;P=0.002)。
  • 总生存更差的独立预测因素包括原发肿瘤高级别T分期(HR 2.12;P=0.021)、RAS突变(HR 1.74;P=0.015)及双突变(HR 3.09;P<0.001)。
  • 在仅接受化疗的独立队列中,双突变患者3年OS为18%,无双突变者为35%(P=0.023)。

临床怎么用

  • 对结直肠癌肝转移患者可考虑检测APC与PIK3CA双突变,以辅助预判术前化疗反应及肝切除后生存风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of the study was to determine the prognostic impact of co-existence of APC and PIK3CA mutations in patients undergoing preoperative chemotherapy and resection for colorectal liver metastases (CLM). BACKGROUND: Co-occurring genetic events have been shown to drive carcinogenesis in multiple malignancies. METHODS: We identified 396 patients with primary colorectal cancer and known somatic mutation status by next-generation sequencing who underwent hepatectomy for CLM (2005-2015). Survival after hepatectomy in patients with double mutation of APC and PIK3CA and others was analyzed. Predictors of pathologic response and survival were determined. The prognostic value of double mutation was evaluated with a separate cohort of 157 patients with CLM undergoing chemotherapy alone. RESULTS: Forty-five patients had double mutation of APC and PIK3CA; 351 did not. Recurrence-free survival (RFS) and overall survival (OS) after hepatectomy were worse in patients with double mutation (3-year RFS, 3.1% vs 20% [P < 0.001]; 3-year OS, 44% vs 84% [P < 0.001]). Independent predictors of major pathologic response were bevacizumab use (odds ratio [OR] 2.22; P = 0.001), tumor size <3 cm (OR 1.97; P = 0.004), wild-type RAS (OR 2.00; P = 0.003), and absence of double mutation (OR 2.91; P = 0.002). Independent predictors of worse OS were primary advanced T category (hazard ratio [HR] 2.12; P = 0.021), RAS mutation (HR 1.74; P = 0.015), and double mutation (HR 3.09; P < 0.001). In the different medical cohort, patients with double mutation had worse 3-year OS of 18%, compared with 35% without double mutation (P = 0.023). CONCLUSIONS: Double mutation of APC and PIK3CA predicts inferior response to preoperative chemotherapy and poor survival in patients with CLM.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Yamashita S, Chun YS, Kopetz SE, et al. APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases. Ann Surg. 2020. PMID: 28379870. doi:10.1097/SLA.0000000000002245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。